Pfizer (PFE) Depreciation & Amortization (CF) (2009 - 2026)

Pfizer (PFE) has 18 years of Depreciation & Amortization (CF) data on file, last reported at $1.6 billion in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $1.6 billion, changed 0.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.6 billion (up 29.08% YoY), and the FY2025 annual result was $6.6 billion, down 6.0% from the prior year.
• Depreciation & Amortization (CF) retreated to $1.6 billion in Q1 2026 per PFE's latest filing, from $1.7 billion in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $3.5 billion in Q4 2022 and troughed at $1.2 billion in Q3 2022.
• A 5-year average of $1.7 billion and a median of $1.6 billion in 2025 frame the typical range for Depreciation & Amortization (CF).
• On a YoY basis, Depreciation & Amortization (CF) climbed as much as 33.87% in 2023 and fell as far as 55.99% in 2023.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $3.5 billion in 2022, then sank by 52.89% to $1.7 billion in 2023, then increased by 5.09% to $1.8 billion in 2024, then declined by 3.87% to $1.7 billion in 2025, then retreated by 4.39% to $1.6 billion in 2026.
• Business Quant data shows PFE's Depreciation & Amortization (CF) at $1.6 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.7 billion in Q3 2025.